**Beyond passive immunity: is there priming of the fetal immune system following vaccination in pregnancy and what are the potential clinical implications?**

Christopher R Wilcox 1 \*, Christine E Jones 2

1: NIHR Clinical Research Facility, Southampton Centre for Biomedical Research, University Hospital Southampton NHS Foundation Trust, Southampton, UK

2: Faculty of Medicine and Institute for Life Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK

**Correspondence:**

* Dr Christopher Wilcox
* NIHR Clinical Research Facility, Southampton Centre for Biomedical Research, C Level West Wing, Mailpoint 218, Southampton General Hospital, Tremona Road, Southampton, SO16 6DY
* Email: christopher.wilcox@soton.ac.uk
* Telephone: 02381204956

**Keywords**

Vaccination

Pregnancy

Fetus

Priming

Antigen

In Utero

Immunity

**Abstract**

Infection is responsible for over half a million neonatal deaths worldwide every year, and vaccination in pregnancy is becoming increasingly recognised as an important strategy for the protection of young infants. Increasing evidence suggests that exposure to maternal infection *in utero* may ‘prime’ the developing immune system, even in the absence of infant infection. It is also possible that *in utero* priming may occur following maternal vaccination, with antigen-specific cellular immune responses detectable *in utero* and at birth. However, this remains a topic of some controversy. This review focusses on the evidence for *in utero* priming and the clinical implications for vaccination in pregnancy, considering whether *in utero* priming following vaccination could provide protection independent of antibody-mediated passive immunity, the possible effects of vaccination on subsequent infant vaccinations, their potential ‘non-specific’ effects, and how the design and timing of vaccination might affect prenatal priming. Looking forwards, we describe other possible options for quantifying antigen-specific cellular responses, including MHC tetramers, novel proliferation and cytokine-based assays, and animal models. Together, these may help us address future research questions and establish more robust evidence of fetal immune system priming.

**Introduction**

Neonates have an inexperienced immune system and infection is responsible for over half a million neonatal deaths worldwide every year (1) . Our current understanding of the functional mechanisms underlying the perinatal and neonatal immune systems remains incomplete (2) . Improving this understanding is crucial for improving infant survival rates, and for the optimisation of interventions, including vaccination in pregnancy and in early life. Vaccination of neonates is challenging as they may mount inadequate protective immunity, and the presence of maternal antibodies may blunt vaccine responses (3) (4) . Vaccination in pregnancy works by boosting the concentration of maternal vaccine-specific antibody, and thus the quantity transported to the fetus across the placenta (5) . This can provide effective protection for the newborn until the period of greatest vulnerability has passed, or until the time of routine infant vaccinations.

Evidence suggests that priming of the fetal immune system may occur in response to maternal infections, environmental and food allergens, and maternal vaccination; with studies showing evidence of adaptive antigen-specific cellular immune responses *in utero* and at birth. However, this remains a topic of some controversy, and our understanding of the underlying mechanisms and clinical implications for vaccination in pregnancy and subsequent infant vaccinations remains poor. In this review, we aim to summarise our current understanding of this field and highlight areas where further research would be most beneficial.

**Transfer of infectious antigens and allergens during pregnancy**

It is now well established that maternal infection during pregnancy can affect the fetal immune system, even in the absence of vertical transmission of pathogens. Maternal infection may alter the susceptibility of infants to later childhood diseases, their response to vaccination, and the development of immunopathological disorders (6) (7) . Furthermore, there is growing evidence that such exposure *in utero* may ‘prime’ the developing immune system, even in the absence of infant infection, resulting in a more activated and mature immunophenotype (8) .

One of the first studies to suggest this phenomenon, published in 1972, followed 12 Eskimo children 10 years after intrauterine exposure to mumps virus during an epidemic (9) . None of the children had evidence of mumps neutralising antibodies, yet 10 had positive skin tests, which the authors suggested was evidence of fetal cellular immune sensitisation which persisted into childhood. Since this time, *in utero* priming has been suggested by both animal models (10) and in studies of uninfected children born to mothers with a range of infections. Many of these studies have been conducted in infants who were HIV-exposed, but remained uninfected. Compared to unexposed infants, a proportion of these infants show enhanced immune activation with a lower percentage of naïve T cells and higher proportion of central memory T cells demonstrating markers of differentiation and senescence, as well as HIV-specific immune responses at birth (11–15) .

Other examples suggesting that priming may occur as a result of maternal infection include studies of Cytomegalovirus (CMV) (16) , Mycobacterium Tuberculosis (8) , Hepatitis B (17), Hepatitis C (18) and plasmodium falciparum (19) . In endemic regions, *in utero* sensitisation to helminths has also been demonstrated by the detection of fetal lymphocyte responses to parasite antigens and the detection of specific immunoglobulins in cord blood. These include filariasis (20) , schistosomiasis (21) , onchocerciasis (22) , and ascariasis (23) . *In utero* exposure to helminths may also influence the neonatal response to subsequent vaccinations. An early study by Malhotra *et al* compared infants sensitised, or not sensitised, to helminth antigens *in utero,* and demonstrated that helminth-specific immune responses persisted into childhood. Furthermore, prenatal sensitization biased T cell immunity induced by BCG vaccination away from type 1 IFN- γ responses, which are associated with protection against mycobacterial infection (24) . However, the underlying mechanisms are complex, and more recent studies investigating whether or not there is a significant suppressive effect of prenatal exposure to maternal parasitic infections on infant vaccine responses (including *Haemophilus influenzae* type B, diphtheria and BCG vaccines) have shown conflicting results (25) (26) .

It should be noted that our understanding of how the fetal immune system actually gets primed by maternal antigen in the absence of fetal infection remains unclear. Low levels of vertical transmission of antigen are possible, and it may be that maternal cells or antigen-loaded micro-vesicles transverse the placental barrier, followed by later clearing (8) (13) . It has also been suggested that transplacental transport of pathogen-derived antigen may occur in the form of immune complexes, mediated by the neonatal Fc receptor (FcRn) (27–29) . Early studies examining tetanus toxoid using a dual *ex vivo* placental perfusion model identified tetanus antigen in both the maternal and fetal circulations (28) (27) . They noted that the ratio of antigen to antibody in the maternal circulation closely matched that observed in the fetal circulation, suggesting a coupling of antigen transfer to the transport of antibody. More recently, May *et al* (29) studied the transplacental transfer of Plasmodium falciparum merozoite surface protein 1 (MSP1), the most abundant malaria blood stage antigen (30) . MSP1 was frequently found in the cord blood of offspring to malaria-infected women, and was often complexed to antibody. Furthermore, using the placental perfusion model, they demonstrated that immunoglobulin G (IgG)-bound MSP1 was present in the fetal perfusate, and confocal laser scanning microscopy revealed MSP1 in the fetal villous stroma, predominately the fetal endothelial cells. How such immune complexes can pass through the fetal endothelial cells into the fetal circulation however, remains unknown. Finally, another possibility is that the fetal immune system may not necessarily be directly affected by contact with infectious antigens, but from exposure to a maternal immune system under the influence of infection (13) (8) . Transplacental transfer of maternal inflammatory mediators, such as cytokines and chemokines, could lead to fetal T cell activation and differentiation. However, this issue is contentious, as recent placental perfusion studies directly investigating whether or not there is any vertical transfer of cytokines have shown conflicting results (31) (32) .

The mechanisms underlying the fetal immune response to such exposure *in utero* are also poorly understood. It is proposed that exposure stimulates fetal innate immune cells, including dendritic cells and macrophages, to produce acute phase cytokines (such as IL-1β), and directs the innate and adaptive immune systems towards an inflammatory response and promotion of fetal T cell priming (14). How the fetal immune system might respond differently to maternal antigen and/or cytokine exposure remains to be seen. With regards to the clinical consequences of such exposure, it is possible that infants may acquire protective immune responses, but alternatively they may also develop immune tolerance, increasing their susceptibility to both homologous and unrelated pathogens (6) (29) . Possible mechanisms of immune tolerance include T cell anergy (33) , and the development of expanded populations of regulatory T cells, which have been shown to supress antigen-specific immune responses to malaria in infants born to mothers with infection during pregnancy (34) (35) . Improving our understanding of this area may therefore have important implications for the screening and management of maternal infections during pregnancy

Whether *in utero* priming occurs in response to environmental allergens (including food and airborne allergens, such as the house dust mite) and whether this contributes towards the development of atopy in the neonate, remains a subject of significant controversy. There is likely to be at least some degree of fetal allergen exposure (36) and allergen-specific IgE is indeed detectable in cord blood. However, it remains debatable whether this is of fetal or maternal origin (37–39) , and there is recent evidence to suggest that this may be predominantly maternal IgE transported across the placenta as IgG/IgE complexes (40) . Furthermore, amongst studies focussing on the development of allergen-specific T-helperpopulations, it remains unclear whether observed cord blood mononuclear cell responses to such exposure necessarily reflect *in utero* sensitisation (41–44) . These findings may have important clinical implications for the aetiology for the atopic disease, and for the development of primary prevention strategies (45) , including maternal allergen avoidance during pregnancy, for which there is limited evidence of protective benefit to date (46) .

**Transfer of vaccine-specific antigens during pregnancy**

Transplacental transfer of IgG during pregnancy provides passive immunity for the newborn, and is crucial for protection against infection in early life. Transcytosis of IgG occurs via pH-dependent binding with FcRn at the placental syncytiotrophoblast layer (47) . IgG is taken up by endocytosis and then binds with FcRn within the acidic environment of early endosomes, where it is protected from proteolytic degradation (48) (49) . IgG is then transcytosed to the basal surface and becomes dissociated from FcRn upon a return to physiological pH. Vaccination in pregnancy works by boosting the concentration of maternal vaccine-specific antibody, and thus the quantity transferred across the placenta to the infant. A number of recent trials have demonstrated that this strategy is safe and efficient means of protecting mother, fetus and infant from infection (50–53), and several countries now routinely offer vaccination to pregnant women against influenza, pertussis and tetanus (54) .

There is some evidence that the fetal immune system may be influenced as a result of vaccination by more than just the passive immunity provided through IgG transfer. As with infectious disease antigens, it may also be sensitised *in utero* to vaccine antigens to which the mother has been exposed during pregnancy, however research in this area remains somewhat scarce. Historically, B cell responses have been studied indirectly by comparing levels of anti-vaccine IgM and IgG antibodies present in cord blood between mothers who were vaccinated and non-vaccinated. Given that IgM does not cross the placental barrier, any differences might suggest that there was sensitisation of fetal B lymphocytes. Early studies in the 1980’s of tetanus vaccination during pregnancy reported the identification of toxoid-specific IgM in some infants (55) , and later work established that the detection of IgM in cord blood was most common when women had undergone vaccination in the second or third trimester (56) . Vaccine-specific IgM in cord blood has also been identified following influenza vaccination (57) (58) , however to our knowledge there is no published data in this area for pertussis vaccination.

More recently, direct measurement of vaccine-influenced fetal T cell priming has been achieved by Rastogi *et al* using MHC tetramers to compare the cord blood of infants born to influenza vaccinated and non-vaccinated mothers (58) . MHC class I and II tetramers permit the detection of antigen-specific T cells at the single-cell level using flow cytometry (59) . They contain four linked human leucocyte antigen (HLA) molecules loaded with a peptide, and this MHC-peptide complex is recognised by a specific subset of T cells via the T cell receptor (60) . MHC tetramers are able to differentiate between naive or memory T cells on the basis of their expression of either the low- or high-molecular weight isoforms of the leukocyte common antigen, CD45RO or CD45RA, respectively (61) . Cord blood T cells are usually considered to be predominantly naïve, due to their low expression of CD45RO (62) (63) .

In their study, Rastogi *et al* demonstrated that the influenza-specific cord T cells in this study were repeatedly CD45RO+, suggesting an effector memory T cell response. Some studies have argued that the antigen-specific fetal T cells observed are not necessarily conventionally primed T-helper memory cells, but instead might represent a transitional population between thymocytes and adult T cells known as ‘recent thymic migrants’ (64) . These cells dominate the human peripheral T cell compartment during the neonatal period and are able to quickly generate T-cell cytokine signals in the absence of conventional T cells (65) . However, the T cell phenotype observed in the study by Rastogi *et al* is not consistent with recent thymic migrants, and instead suggests successful generation of an effector memory T cell response as a result of *in utero* priming by maternal influenza vaccination.

**What is the potential clinical relevance of these findings for vaccination in pregnancy?**

It is possible that *in utero* priming following vaccination could benefit the neonate by providing protection independent of antibody-mediated passive immunity. This may be particularly important for infections mediated by memory T cell immunopathology such as Respiratory Syncytial Virus (RSV) (66–68) . RSV is the leading viral cause of lower respiratory tract infection in infants and a major cause of childhood morbidity and mortality globally (69) . Whilst no vaccine against RSV is yet approved for use in pregnancy, a number of candidates are currently in development, one of which is undergoing international phase III efficacy trials in pregnant women (NCT02624947) (54) . For such an infection, providing passive immunity alone through generation of high antibody titres will likely be insufficient to prevent disease in every individual (70) . Yet, results from both mouse models and experimental human challenge studies suggest if vaccines elicit RSV-specific memory CD8 T cell responses, this may promote more effective viral clearance upon infection, and promote longer-lived immunity (66) (71) .

It has also been established that presence of maternal vaccine-induced antibodies can interfere with the concentration of subsequent infant vaccine responses (3) (4) . Vaccination in pregnancy against pertussis, for example, reduces infant morbidity and mortality from whooping cough (51) , but also reduces the antibody response to infant pertussis vaccination (72) (73) . The effect of vaccine-induced *in utero* fetal T cell priming on subsequent infant T cell responses to postnatal vaccines is unknown, however to our knowledge this blunting effect has not been described for infants’ cellular immune responses to date (74) . Furthermore, the clinical significance of blunting of infant antibody responses is still poorly understood.

It is also becomingly increasingly recognised that vaccination may have immune modulatory effects beyond initiating antigen-specific [adaptive responses](http://www.sciencedirect.com/topics/medicine-and-dentistry/adaptive-response), termed ‘non-specific effects’ (75) . Recent randomised and observation studies in Africa have shown non-specific beneficial effects on survival following infant vaccination with live vaccines against measles and BCG, and may reduce all-cause mortality risk by 20-50% for those up to 5 years-of-age (76–79) . It has been suggested that these effects may particularly benefit low birth weight infants during the neonatal period because of reduced risk of respiratory infections and sepsis (76) . A possible mechanism to explain these heterologous effects is the phenomenon of innate immune response training, which involves epigenetic reprogramming of monocytes leading to increased cytokine production in response to antigens unrelated to the original stimulus (80) . Vaccination during pregnancy could therefore also have non-specific effects in the mother, fetus or newborn, and whilst this hasn’t yet been formally investigated to our knowledge, one recent study did show that MF59-adjuvanted influenza vaccination during pregnancy led to an altered [cytokine](http://www.sciencedirect.com/topics/medicine-and-dentistry/cytokines) production profile in the nasal mucosa of 4-week-old infants compared with infants born to unvaccinated mothers (81) . The underlying mechanisms, clinical implications and the possible role of *in utero* priming remains to be determined.

Finally, it is also worth considering how the design and delivery of vaccination might affect the transplacental transfer of vaccine antigen, and the subsequent effect on fetal immune responses. Firstly, the timing of exposure with respect to gestational age, may have an impact upon priming. Most studies to date have been conducted within the context of allergen exposure, and have suggested that a cut-off at around 20-22 weeks gestation might favour *in utero* sensitisation to allergens (82) (83) . Jones *et al*, for example, obtained blood samples from fetuses and premature babies to determine at what stage the fetal immune system produced a significant proliferative response to common allergens, including house dust mite, cat fur and birth tree pollen (82) . The authors found significantly higher PBMC proliferative response ratios in those infants who had been exposed to allergens beyond 22 weeks gestation. A study by Vanderbeeken *et al* focussing on *in utero* sensitisation to tetanus vaccination also showed similar results, with detection of tetanus-specific IgM in cord blood occurring most often when women had undergone vaccination in the second or third trimester (56) . Improving our understanding in this area, and establishing whether/when during gestation an optimum ‘window of opportunity’ occurs for prenatal T cell priming may therefore inform the debate regarding the optimum time period for maternal vaccination. A number of other variables relating to vaccine design are also known to have an influence on vaccine efficacy and the resulting pattern of initial T cells responses, including vaccine type, dose and route (84) (4) . Vaccine adjuvants may also be used to guide the magnitude and type of adaptive response to vaccines (85) . These factors may therefore conceivably have an effect on the quantity and/or quality of vaccine antigen that is able to transverse the placental barrier, however direct research in this area is currently lacking.

**What further methods could be employed to study vaccine antigen priming?**

There is clearly a paucity of research on the topic of vaccine-antigen priming, and the studies described above have been limited to using measurements of cord blood IgM and MHC tetramers. MHC tetramers offer a direct means of detecting antigen-specific T cells (59) , however, the downside to their use is that their design requires considerable prior knowledge of the major pathogen epitopes recognised by human T cells, as well as the HLA type of each subject being studied (59) (60) . This information might not be readily available for many vaccine studies, and may limit their use in human trials. Another limitation of these studies is that they were conducted over short periods, and future research may benefit from repeated measurements of antigen-specific T cells over several months after birth, as this would provide further insight into the development of memory T cells.

Below we discuss other possible options for identifying vaccine-induced priming in future studies (including proliferation assays, cytokine-based assays and animal studies) which could be undertaken without knowledge of specific antigen epitopes and MHC restriction elements. It should be noted that the interpretation of proliferative immune responses as supposed evidence of *in utero* priming still remains a subject of debate (43) (44) . Furthermore, these measurements are indirect and may be prone to experimental variability due to differences in initial cell count and media/culture conditions (86–88) .

**Proliferation assays**

One method that may be used to measure antigen-specific T cell proliferation is flow cytometry, of which assays include fluorescent dye dilution (using Oregon Green or carboxyfluorescein diacetate succinimidyl ester (CFSE)) (89) (90) , and those detecting 5-bromo-2′-deoxyuridine (BrdU) using fluorochrome-conjugated antibody staining (91) . Limitations of dye dilution include its cellular toxicity (92) (93) and sensitivity to pH and light (89) , and the major limitation of using BrDU is that it inhibits cell cycle progression, meaning that only cells progressing through S-phase in less than 24 hours will be identified (94) .

A newer method which could be used in future studies to more reliably quantify antigen-specific T cell proliferation *in vitro* following vaccination is intracellular expression of the nuclear protein, Ki67 (94) *.* To date, this protein has been used most commonly as a marker of tumour cell proliferation in cancer biology (95) . Ki67 helps regulate cell division and is active throughout the cell cycle, but is not present in quiescent cells and during DNA repair, making it an ideal marker for determining the growth of a specific cell population (96) . Furthermore, the assay doesn’t require washing or incubation prior to culture, and cells are not exposed to toxic compounds. Soares *et al* found that Ki67 was expressed in CD4+ and CD8+ T cells that had undergone *in vitro* proliferation in human whole blood or peripheral blood mononuclear cell assays with antigens, and the results correlated strongly with those demonstrated by traditional flow cytometry (94) . T cells cultured in the absence of antigen did not express Ki67, and the assay was able to detect vaccine-specific CD4+ T cell proliferation after infant vaccination with tetanus toxoid. These findings support work by others who have demonstrated that intracellular Ki67 expression can be used to directly measure specific effector T cell responses induced by vaccination *ex vivo*, or after *in vitro* cell culture (8) (97–99) . One limitation of Ki67 as a marker is, unlike using dye dilution assays, one cannot calculate the number of proliferation cycles that have occurred, and therefore cannot estimate the original number of precursor cells (100) .

**Cytokine-based assays**

Cytokine-based assays are another possible option for future studies to characterise the immunological response to vaccines in pregnancy, as naïve and memory T cells each display distinct cytokine signatures. Memory cells produce cytokines such as IFN-γ within 20 hours following antigen challenge, whereas naïve T cells must first undergo proliferation and differentiation before they can express such cytokines (101) (102) . Traditional cytokine-based assays include enzyme-linked immunosorbent assay (ELISA), and cytometric bead array (CBA), and more recently, enzyme-linked immunosorbent spot (ELISpot), FluroSpot, and intracellular cytokine staining (ICS) assays have been developed which can measure cytokine production on a per-cell basis (88) . These measurements can be performed on whole blood or cryopreserved PBMCs, and allow one to quantify functional populations of antigen-specific memory T cells (103)(104) . ELISpot in particular has emerged as one of the most reliable methods of evaluating human immune responses to vaccines (105) (106) . When using frozen PBMCs from the same donors however, tetramer assays have been shown to have better precision and linearity than ICS or ELISpot (107) .

**Animal studies**

Finally, animal models may offer the opportunity for more in-depth *in vivo* studies to probe the mechanics of *in utero* sensitisation. A variety of species have been used to study the safety and immunogenicity of maternal vaccination to date (108) , however to our knowledge this approach hasn’t yet been used to formally investigate the concept of priming following vaccination. T cell priming following exposure to infectious disease has been demonstrated by work in rodents, including an elegant study by Rahman *et al* (10) . They demonstrated that mycobacterial antigens administered to mothers during the 2nd week of gestation were transported across the placenta, and that their offspring displayed higher specific T cell responses compared to offspring of untreated mothers. Antigen tracing was accomplished using fluorescent nanocrystals, and antigens conjugated with fluorescent Qdot were visible on the placental tissue as well as on the fetal tissue. Animal models involving real-time *in vivo* antigen tracing therefore offer an exciting avenue for future research. One downside of murine models is that B cell priming cannot be studied, as the appearance of B cells in mice and rats is delayed compared with humans and no B cells have been observed before birth.

**Conclusions**

Increasing evidence suggests that exposure to maternal infection *in utero* may ‘prime’ the developing immune system, even in the absence of infant infection, and some evidence suggests that this may also occur following vaccination. Whilst this exciting field of research continues to expand, our understanding of the underlying mechanisms remains poor, and further work is required to elucidate the possible clinical implications. It is possible that *in utero* priming following vaccination could benefit the neonate by providing protection independent of antibody-mediated passive immunity, however the possible effects of vaccination on subsequent infant vaccinations, their potential ‘non-specific’ effects, and how the design and timing of vaccination may effect prenatal priming remain important questions to answer.

Looking forwards, researchers should consider other possible options for quantifying antigen-specific T cells in order to establish firm evidence of priming following vaccination, as controversy remains over whether observed cell responses necessarily reflect *in utero* sensitisation. We have discussed the use of MHC tetramers, as well as other novel proliferation and cytokine-based assays, and animal models using *in vivo* antigen tracing. Future research platforms would benefit from multi-disciplinary collaborations and utilising variety of placental models. Improving our understanding of the perinatal and neonatal immune systems is crucial for improving infant survival rates and the optimisation of vaccination in pregnancy and in early life, especially in developing countries where the burden of infectious disease is the highest.

**Acknowledgements**

None

**Conflict of interest statement**

CRW and CEJ are investigators for clinical trials done on behalf of University of Southampton and University Hospital Southampton NHS Foundation Trust, sponsored by various vaccine manufacturers including Novavax for a respiratory syncytial virus vaccine, but receive no personal funding for these activities.

**Funding**

CEJ has received funding from the IMmunising PRegnant women and INfants neTwork (IMPRINT), funded by the GCRF Networks in Vaccines Research and Development, which was co-funded by the MRC and BBSRC; the National Vaccine Program Office (NVPO); Bill & Melinda Gates Foundation (Grant number OPP1119788), Global Alignment of Immunization Safety Assessment in pregnancy (GAIA) and the National Institute for Health Research (NIHR) under its Research for Patient Benefit (RfPB) Programme (Grant number PB-PG-0215-36120 ). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

**Author contributions statement**

CRW designed and wrote the article. CEJ conceived, designed and critically revised the article.

**References**

 1. Lawn J, Blencowe H, Oza S, You D, Lee A, Waiswa P, Lalli M, Bhutta Z, Barros A, Christian P, et al. Every Newborn: progress, priorities, and potential beyond survival. *Lancet* (2014) **384**:189–205. doi:10.1016/S0140-6736(14)60496-7

2. Basha S, Surendran N, Pichichero M. Immune responses in neonates. *Expert Rev Clin Immunol* (2014) **10**:1171–1184. doi:10.1586/1744666X.2014.942288

3. Ladhani SN, Andrews NJ, Southern J, Jones CE, Amirthalingam G, Waight PA, England A, Matheson M, Bai X, Findlow H, et al. Antibody Responses After Primary Immunization in Infants Born to Women Receiving a Pertussis-containing Vaccine During Pregnancy: Single Arm Observational Study With a Historical Comparator. *Clin Infect Dis* (2015) **61**:1637–1644. doi:10.1093/cid/civ695

4. Faucette AN, Pawlitz MD, Pei B, Yao F, Chen K. Immunization of pregnant women: Future of early infant protection. *Hum Vaccin Immunother* (2015) **11**:2549–55. doi:10.1080/21645515.2015.1070984

5. Wilcox CR, Holder B, Jones CE. Factors Affecting the FcRn-Mediated Transplacental Transfer of Antibodies and Implications for Vaccination in Pregnancy. *Front Immunol* (2017) **8**:1294. doi:10.3389/fimmu.2017.01294

6. Dauby N, Goetghebuer T, Kollmann TR, Levy J, Marchant A. Uninfected but not unaffected: chronic maternal infections during pregnancy, fetal immunity, and susceptibility to postnatal infections. *Lancet Infect Dis* (2012) **12**:330–40. doi:10.1016/S1473-3099(11)70341-3

7. LaBeaud DA, Malhotra I, King MJ, King CL, King CH. Do Antenatal Parasite Infections Devalue Childhood Vaccination? PLoS Negl Trop Dis (2009) **3**:e442. doi:10.1371/journal.pntd.0000442

8. Jones C, Hesseling A, Tena-Coki N, Scriba T, Chegou N, Kidd M, Wilkinson R, Kampmann B. The impact of HIV exposure and maternal Mycobacterium tuberculosis infection on infant immune responses to bacille Calmette-Guérin vaccination. *Aids* (2015) **29**:155. doi:10.1097/QAD.0000000000000536

9. Aase J, Noren G, Reddy V, St.Geme J. Mumps-Virus Infection in Pregnant Women and the Immunologic Response of Their Offspring. *New Engl J Med* (1972) **286**:1379–1382. doi:10.1056/NEJM197206292862603

10. Rahman M, Dégano I, Singh M, Fernández C. Influence of maternal gestational treatment with mycobacterial antigens on postnatal immunity in an experimental murine model. *PloS one* (2010) **5**:e9699. doi:10.1371/journal.pone.0009699

11. Ono, Santos AM dos, Succi RC de, Machado DM, Angelis DSA de, Salomão, Kallás EG, Moraes-Pinto MI de. Imbalance of naive and memory T lymphocytes with sustained high cellular activation during the first year of life from uninfected children born to HIV-1-infected mothers on HAART. *Braz J Med Biol Res* (2008) **41**:700–708. doi:10.1590/S0100-879X2008000800011

12. Clerici, Saresella, Colombo, Fossati, Sala, Bricalli, Villa, Ferrante, Dally, Vigano’. T-lymphocyte maturation abnormalities in uninfected newborns and children with vertical exposure to HIV. *Blood* (2000) **96**:3866–71.

13. Miles D, Gadama L, Gumbi A, Nyalo F, Makanani B, Heyderman R. Human immunodeficiency virus (HIV) infection during pregnancy induces CD4 T‐cell differentiation and modulates responses to Bacille Calmette‐Guérin (BCG) vaccine in HIV‐uninfected infants. *Immunology* (2010) **129**:446–454. doi:10.1111/j.1365-2567.2009.03186.x

14. Bunders M, Hamme J, Jansen M, Boer K, Kootstra N, Kuijpers T. Fetal exposure to HIV-1 alters chemokine receptor expression by CD4+T cells and increases susceptibility to HIV-1. *Sci Reports* (2014) **4**:6690. doi:10.1038/srep06690

15. Kuhn L, Meddows‐Taylor S, Gray G, Tiemessen C. Human Immunodeficiency Virus (HIV)–Specific Cellular Immune Responses in Newborns Exposed to HIV In Utero. *Clin Infect Dis* (2002) **34**:267–276. doi:10.1086/338153

16. Marchant A, Appay V, Sande M, Dulphy N, Liesnard C, Kidd M, Kaye S, Ojuola O, Gillespie G, Cuero A, et al. Mature CD8+ T lymphocyte response to viral infection during fetal life. *J Clin Invest* (2003) **111**:1747–1755. doi:10.1172/JCI17470

17. Bertoletti A, Kafetzis D, Koumbi L, Machaira M, Papadopoulos N, Anastasiadou V, Papaevangelou V, Goh W. Hepatitis B-specific T helper cell responses in uninfected infants born to HBsAg+/HBeAg− mothers. *Cell Mol Immunol* (2010) **7**:454. doi:10.1038/cmi.2010.34

18. Babik J, Cohan D, Monto A, Hartigan-O’Connor D, McCune J. The Human Fetal Immune Response to Hepatitis C Virus Exposure in Utero. *J Infect Dis* (2011) **203**:196–206. doi:10.1093/infdis/jiq044

19. Metenou S, Suguitan AL, Long C, Leke RG, Taylor D. Fetal immune responses to Plasmodium falciparum antigens in a malaria-endemic region of Cameroon. *J Immunol* (2007) **178**:2770–7.

20. Achary KG, Bal MS, Mandal NN, Satapathy AK. Increased IgG antibody responses to excretory/secretory antigens in neonates born from mothers infected with filarial nematodes. *J Helminthol* (2017) **91**:752–756. doi:10.1017/S0022149X16000778

21. Malhotra I, Ouma J, Wamachi A, Kioko J, Mungai P, Omollo A, et al. In utero exposure to helminth and mycobacterial antigens generates cytokine responses similar to that observed in adults. *J Clin Invest* (1997) **99**: 1759-1766. doi:10.1172/JCI119340

22. Soboslay P, Geiger S, Drabner B, Banla M, Batchassi E, Kowu L, Stadler A, Schulz-Key H. Prenatal immune priming in onchocerciasis—Onchocerca volvulus-specific cellular responsiveness and cytokine production in newborns from infected mothers. *Clin Exp Immunol* (1999) **117**:130. doi:10.1046/j.1365-2249.1999.00906.x

23. Guadalupe I, Mitre E, Benitez S, Chico ME, Nutman TB, Cooper PJ. Evidence for in utero sensitization to Ascaris lumbricoides in newborns of mothers with ascariasis. *J Infect Dis* (2009) **199**:1846–1850. doi:10.1086/599214

24. Malhotra I, Mungai P, Wamachi A, Kioko J, Ouma J, Kazura J, King C. Helminth- and Bacillus Calmette-Guérin-induced immunity in children sensitized in utero to filariasis and schistosomiasis. *J Immunol* (1999) **162**:6843–8.

25. Malhotra I, McKibben M, Mungai P, McKibben E, Wang X, Sutherland LJ, Muchiri EM, King CH, King CL, LaBeaud A. Effect of antenatal parasitic infections on anti-vaccine IgG levels in children: a prospective birth cohort study in Kenya. *PLoS Negl Trop Dis* (2015) **9**:e0003466. doi:10.1371/journal.pntd.0003466

26. Nash S, Mentzer AJ, Lule SA, Kizito D, Smits G, Klis FR van der, Elliott AM. The impact of prenatal exposure to parasitic infections and to anthelminthic treatment on antibody responses to routine immunisations given in infancy: Secondary analysis of a randomised controlled trial. *PLoS Negl Trop Dis* (2017) **11**:e0005213. doi:10.1371/journal.pntd.0005213

27. Malek A, Sager R, Schneider H. Transport of Proteins Across the Human Placenta. *Am J Reprod Immunol* (1998)347–351. doi:10.1111/j.1600-0897.1998.tb00064.x

28. Malek A, Sager R, Lang A, Schneider H. Protein Transport Across the In Vitro Perfused Human Placenta. *Am J Reprod Immunol* (1997)263–271. doi:10.1111/j.1600-0897.1997.tb00513.x

29. May K, Grube M, Malhotra I, Long C, Singh S, Mandaliya K, Siegmund W, Fusch C, Schneider H, King C. Antibody-Dependent Transplacental Transfer of Malaria Blood-Stage Antigen Using a Human Ex Vivo Placental Perfusion Model. *PLoS ONE* (2009)e7986. doi:10.1371/journal.pone.0007986

30. Holder A, Lockyer M, Odink K, Sandhu J, Riveros-Moreno V, Nicholls S, Hillman Y, Davey L, Tizard M, Schwarz R, et al. Primary structure of the precursor to the three major surface antigens of Plasmodium falciparum merozoites. *Nature* (1985)317270a0. doi:10.1038/317270a0

31. Aaltonen R, Heikkinen T, Hakala K, Laine K, Alanen A. Transfer of proinflammatory cytokines across term placenta. *Obstet Gynecol* (2005) **106**:802–7. doi:10.1097/01.AOG.0000178750.84837.ed

32. Zaretsky MV, Alexander JM, Byrd W, Bawdon RE. Transfer of inflammatory cytokines across the placenta. *Obstet Gynecol* (2004) **103**:546–50. doi:10.1097/01.AOG.0000114980.40445.83

33. Fathman G, Lineberry N. Molecular mechanisms of CD4+ T-cell anergy. *Nat Rev Immunol* (2007) **7**:nri2131. doi:10.1038/nri2131

34. Mold J, Michaëlsson J, Burt T, Muench M, Beckerman K, Busch M, Lee T-H, Nixon D, McCune J. Maternal Alloantigens Promote the Development of Tolerogenic Fetal Regulatory T Cells in Utero. *Science* (2008) **322**:1562–1565. doi:10.1126/science.1164511

35. Brustoski K, Möller U, Kramer M, Hartgers F, Kremsner P, Krzych U, Luty A. Reduced Cord Blood Immune Effector-Cell Responsiveness Mediated by CD4+ Cells Induced in Utero as a Consequence of Placental Plasmodium falciparum Infection. *J Infect Dis* (2006) **193**:146–154. doi:10.1086/498578

36. Holloway J, Warner J, Vance G, Diaper N, Warner J, Jones C. Detection of house-dust-mite allergen in amniotic fluid and umbilical-cord blood. *Lancet* (2000) **356**:1900–2. doi:10.1016/S0140-6736(00)03265-7

37. Joerink, Rindsjö, Stenius, Alm, Lilja, Grönlund, Scheynius. Evidence for allergen‐specific IgE of maternal origin in human placenta. *Allergy* (2009) **64**:905–912. doi:10.1111/j.1398-9995.2009.01941.x

38. Pfefferle P, Sel S, Ege M, Büchele G, Blümer N, Krauss-Etschmann S, Herzum I, Albers C, Lauener R, Roponen M, et al. Cord blood allergen-specific IgE is associated with reduced IFN-γ production by cord blood cells: The Protection against Allergy—Study in Rural Environments (PASTURE) study. *J Allergy Clin Immun* (2008) **122**:711–716. doi:10.1016/j.jaci.2008.06.035

39. Wolsk H, Andersen M, Bisgaard H, Bønnelykke K. No evidence of intrauterine sensitization against inhalant allergens. *J Allergy Clin Immun* (2017) **140**:286–288.e3. doi:10.1016/j.jaci.2016.10.048

40. Bundhoo, Paveglio, Rafti, Dhongade, Blumberg, Matson. Evidence that FcRn mediates the transplacental passage of maternal IgE in the form of IgG anti‐IgE/IgE immune complexes. *Clin Exp Allergy* (2015) **45**:1085–1098. doi:10.1111/cea.12508

41. Prescott S, Macaubas C, Holt B, Smallacombe T, Loh R, Sly P, Holt P. Transplacental priming of the human immune system to environmental allergens: universal skewing of initial T cell responses toward the Th2 cytokine profile. *J Immunol* (1998) **160**:4730–7.

42. Rowe J, Kusel M, Holt B, Suriyaarachchi D, Serralha M, Hollams E, Yerkovich S, Subrata L, Ladyman C, Sadowska A, et al. Prenatal versus postnatal sensitization to environmental allergens in a high-risk birth cohort. *J Allergy Clin Immun* (2007) **119**:1164–1173. doi:10.1016/j.jaci.2007.02.016

43. Holt PG. Prenatal versus postnatal priming of allergen specific immunologic memory: The debate continues. *J Allergy Clin Immun* (2008) **122**:717–718. doi:10.1016/j.jaci.2008.08.019

44. Platts-Mills T, Woodfolk JA. Cord blood proliferative responses to inhaled allergens: Is there a phenomenon? *J Allergy Clin Immun* (2000) **106**:441–443. doi:10.1067/mai.2000.109427

45. Toit G du, Tsakok T, Lack S, Lack G. Prevention of food allergy. *J Allergy Clin Immun* (2016) **137**:998–1010. doi:10.1016/j.jaci.2016.02.005

46. Kramer M, Kakuma R. Maternal dietary antigen avoidance during pregnancy or lactation, or both, for preventing or treating atopic disease in the child. *Cochrane Database Syst Rev* (2012) **9**:CD000133. doi:10.1002/14651858.CD000133.pub3

47. Firan M, Bawdon R, Radu C, Ober R, Eaken D, Antohe F, Ghetie V, Ward S. The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of γ-globulin in humans. *Int Immunol* (2001) **13**:993–1002. doi:10.1093/intimm/13.8.993

48. Leitner K, Ellinger I, Grill M, Brabec M, Fuchs R. Efficient apical IgG recycling and apical-to-basolateral transcytosis in polarized BeWo cells overexpressing hFcRn. *Placenta* (2006) **27**:799–811. doi:10.1016/j.placenta.2005.08.008

49. Ober R, Martinez C, Vaccaro C, Zhou J, Ward. Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. *J Immunol* (2004) **172**:2021–9.

50. Poehling KA, Szilagyi PG, Staat MA, Snively BM, Payne DC, Bridges CB, Chu SY, Light LS, Prill MM, Finelli L, et al. Impact of maternal immunization on influenza hospitalizations in infants. *Am J Reprod Immunol* (2011) **204**:S141–8. doi:10.1016/j.ajog.2011.02.042

51. Amirthalingam G, Andrews N, Campbell H, Ribeiro S, Kara E, Donegan K, Fry NK, Miller E, Ramsay M. Effectiveness of maternal pertussis vaccination in England: an observational study. *Lancet* (2014) **384**:1521–1528. doi:10.1016/S0140-6736(14)60686-3

52. Zaman K, Roy E, Arifeen SE, Rahman M, Raqib R, Wilson E, Omer SB, Shahid NS, Breiman RF, Breiman RE, et al. Effectiveness of maternal influenza immunization in mothers and infants. *N Engl J Med* (2008) **359**:1555–64. doi:10.1056/NEJMoa0708630

53. Madhi SA, Cutland CL, Kuwanda L, Weinberg A, Hugo A, Jones S, Adrian PV, Niekerk N van, Treurnicht F, Ortiz JR, et al. Influenza Vaccination of Pregnant Women and Protection of Their Infants. *N Engl J Med* (2014) **371**:918–931. doi:10.1056/NEJMoa1401480

54. Jones C, Calvert A, Doare K. Vaccination in Pregnancy—Recent Developments. *Pediatr Infect Dis J* (2018) **37**:191. doi:10.1097/INF.0000000000001822

55. Gill, Repetti, Metlay, Rabin, Taylor, Thompson, Cortese. Transplacental immunization of the human fetus to tetanus by immunization of the mother. *J Clin Invest* (1983) **72**:987–996. doi:10.1172/JCI111071

56. Vanderbeeken Y, Sarfati M, Bose R, Delespesse G. In Utero Immunization of the Fetus to Tetanus by Maternal Vaccination During Pregnancy. *Am J Reprod Immunol Microbiol* (1985) **8**:39–42. doi:10.1111/j.1600-0897.1985.tb00347.x

57. Englund, Mbawuike, Hammill, Holleman, Baxter, Glezen. Maternal immunization with influenza or tetanus toxoid vaccine for passive antibody protection in young infants. *J Infect Dis* (1993) **168**:647–56. doi:10.1093/infdis/168.3.647

58. Rastogi D, Wang C, Mao X, Lendor C, Rothman PB, Miller RL. Antigen-specific immune responses to influenza vaccine in utero. *J Clin Invest* (2007) **117**:1637–46. doi:10.1172/JCI29466

59. Massilamany C, Krishnan B, Reddy J. Major Histocompatibility Complex Class II Dextramers: New Tools for the Detection of antigen‐Specific, CD4 T Cells in Basic and Clinical Research. *Scand J Immunol* (2015) **82**:399–408. doi:10.1111/sji.12344

60. Altman J, Moss P, Goulder P, Barouch D, McHeyzer-Williams M, Bell J, McMichael A, Davis M. Phenotypic analysis of antigen-specific T lymphocytes. *Science* (1996) **274**:94–6. doi:10.1126/science.274.5284.94

61. Clement L. Isoforms of the CD45 common leukocyte antigen family: markers for human T-cell differentiation. *J Clin Immunol* (1992) **12**:1–10. doi:10.1007/BF00918266

62. Vries E de, Bruin-Versteeg S de, Comans-Bitter W, Groot R de, Hop W, Boerma G, Lotgering F, Dongen J van. Longitudinal survey of lymphocyte subpopulations in the first year of life. *Pediatr Res* (2000) **47**:528–37. doi:10.1203/00006450-200004000-00019

63. Tosato F, Bucciol G, Pantano G, Putti M, Sanzari MC, Basso G, Plebani M. Lymphocytes subsets reference values in childhood. *Cytometry A* (2015) **87**:81–85. doi:10.1002/cyto.a.22520

64. Thornton C, Upham J, Wikström M, Holt B, White G, Sharp M, Sly P, Holt P. Functional Maturation of CD4 + CD25 + CTLA4 + CD45RA + T Regulatory Cells in Human Neonatal T Cell Responses to Environmental Antigens/Allergens. *J Immunol* (2004) **173**:3084–3092. doi:10.4049/jimmunol.173.5.3084

65. Hassan J, Reen D. Human recent thymic emigrants--identification, expansion, and survival characteristics. *J Immunol* (2001) **167**:1970–6. doi:10.4049/jimmunol.167.4.1970

66. Schmidt M, Knudson C, Hartwig S, Pewe L, Meyerholz D, Langlois R, Harty J, Varga S. Memory CD8 T cells mediate severe immunopathology following respiratory syncytial virus infection. *Plos Pathog* (2018) **14**:e1006810. doi:10.1371/journal.ppat.1006810

67. Varga S, Wang X, Welsh R, Braciale T. Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells. *Immunity* (2001) **15**:637–46. doi:10.1016/S1074-7613(01)00209-6

68. Castilow E, Varga S. Overcoming T-cell-mediated immunopathology to achieve safe respiratory syncytial virus vaccination. *Future Virol* (2008) **3**:445–454. doi:10.2217/17460794.3.5.445

69. Hall C, Weinberg G, Iwane M, Blumkin A, Edwards K, Staat M, Auinger P, Griffin M, Poehling K, Erdman D, et al. The Burden of Respiratory Syncytial Virus Infection in Young Children. *New Engl J Med* (2009) **360**:588–598. doi:10.1056/NEJMoa0804877

70. Ochola R, Sande C, Fegan G, Scott P, Medley G, Cane P, Nokes J. The Level and Duration of RSV-Specific Maternal IgG in Infants in Kilifi Kenya. *Plos One* (2009) **4**:e8088. doi:10.1371/journal.pone.0008088

71. Jozwik A, Habibi M, Paras A, Zhu J, Guvenel A, Dhariwal J, Almond M, Wong E, Sykes A, Maybeno M, et al. RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection. *Nat Commun* (2015) **6**:10224. doi:10.1038/ncomms10224

72. Feunou P, Mielcarek N, Locht C. Reciprocal interference of maternal and infant immunization in protection against pertussis. *Vaccine* (2016) **34**:1062–1069. doi:10.1016/j.vaccine.2016.01.011

73. Maertens K, Caboré R, Huygen K, Vermeiren S, Hens N, Damme P, Leuridan E. Pertussis vaccination during pregnancy in Belgium: Follow-up of infants until 1 month after the fourth infant pertussis vaccination at 15 months of age. *Vaccine* (2016) **34**:3613–3619. doi:10.1016/j.vaccine.2016.04.066

74. Gans H, DeHovitz R, Forghani B, Beeler J, Maldonado Y, Arvin AM. Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of life. *Vaccine* (2003) **21**:3398–405.

75. Aaby P, Kollmann TR, Benn C. Nonspecific effects of neonatal and infant vaccination: public-health, immunological and conceptual challenges. *Nat Immunol* (2014) **15**:895–899. doi:10.1038/ni.2961

76. Aaby P, Roth A, Ravn H, Napirna B, Rodrigues A, Lisse I, Stensballe L, Diness B, Lausch K, Lund N, et al. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? *J Infect Dis* (2011) **204**:245–52. doi:10.1093/infdis/jir240

77. Aaby P, Martins CL, Garly M-L, Balé C, Andersen A, Rodrigues A, Ravn H, Lisse IM, Benn CS, Whittle HC. Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial. *BMJ* (2010) **341**:c6495. doi:10.1136/bmj.c6495

78. Elguero E, Simondon KB, Vaugelade J, Marra A, Simondon F. Non‐specific effects of vaccination on child survival? A prospective study in Senegal. *Trop Med Int Health* (2005) **10**:956–960. doi:10.1111/j.1365-3156.2005.01479.x

79. Nankabirwa V, Tumwine JK, Mugaba PM, Tylleskär T, Sommerfelt H, Group P-. Child survival and BCG vaccination: a community based prospective cohort study in Uganda. *BMC Public Health* (2015) **15**:175. doi:10.1186/s12889-015-1497-8

80. Kleinnijenhuis J, Quintin J, Preijers F, Benn C, Joosten L, Jacobs C, Loenhout J van, Xavier R, Aaby P, Meer J van der, et al. Long-Lasting Effects of BCG Vaccination on Both Heterologous Th1/Th17 Responses and Innate Trained Immunity. *J Innate Immun* (2013) **6**:152–158. doi:10.1159/000355628

81. Bischoff AL, Følsgaard NV, Vissing NH, Birch S, Brix S, Bisgaard H. Airway mucosal immune-suppression in neonates of mothers receiving A(H1N1)pnd09 vaccination during pregnancy. *Pediatr Infect Dis J* (2015) **34**:84–90. doi:10.1097/inf.0000000000000529

82. Jones A, Miles E, Warner W-, Colwell B, Bryant T, Warner J. Fetal peripheral blood mononuclear cell proliferative responses to mitogenic and allergenic stimuli during gestation. *Pediatr Allergy Immunol* (1996) **7**:109–116. doi:10.1111/j.1399-3038.1996.tb00117.x

83. Szépfalusi Z, Pichler J, Elsässer S, Duren K van, Ebner C, Bernaschek G, Urbanek R. Transplacental priming of the human immune system with environmental allergens can occur early in gestation. *J Allergy Clin Immun* (2000) **106**:530–536. doi:10.1067/mai.2000.108710

84. Estcourt M, Létourneau S, McMichael A, Hanke T. Vaccine route, dose and type of delivery vector determine patterns of primary CD8+ T cell responses. *Eur J Immunol* (2005)2532–2540. doi:10.1002/eji.200535184

85. Coffman R, Sher A, Seder R. Vaccine Adjuvants: Putting Innate Immunity to Work. *Immunity* (2010) **33**:492–503. doi:10.1016/j.immuni.2010.10.002

86. Hobeika AC, Morse MA, Osada T, Ghanayem M, Niedzwiecki D, Barrier R, Lyerly HK, Clay TM. Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis. *J Immunother* (2005) **28**:63–72.

87. Leroux-Roels G, Hecke E Van, Michielsen W, Voet P, Hauser P, Pêtre J. Correlation between in vivo humoral and in vitro cellular immune responses following immunization with hepatitis B surface antigen (HBsAg) vaccines. *Vaccine* (1994) **12**:812–8.

88. Saade F, Gorski S, Petrovsky N. Pushing the frontiers of T-cell vaccines: accurate measurement of human T-cell responses. *Expert Rev Vaccines* (2014) **11**:1459–1470. doi:10.1586/erv.12.125

89. Wallace PK, Tario JD, Fisher JL, Wallace SS, Ernstoff MS, Muirhead KA. Tracking antigen‐driven responses by flow cytometry: Monitoring proliferation by dye dilution. *Cytometry A* (2008) **73**:1019–1034. doi:10.1002/cyto.a.20619

90. Magg T, Albert MH. Tracking cell proliferation using the far red fluorescent dye SNARF‐1. *Cytometry B Clin Cytom* (2007) **72**:458–464. doi:10.1002/cyto.b.20180

91. Rosato, Jabbour, Ponce, Kavanagh, Takaro, Hill, Poot, Rabinovitch, Faustman. Simultaneous analysis of surface marker expression and cell cycle progression in human peripheral blood mononuclear cells. *J Immunol Methods* (2001) **256**:35–46.

92. Ka J, Budinsky V, Spisek R, Bartunkova J. Assessment of lymphocyte proliferation: CFSE kills dividing cells and modulates expression of activation markers. *Cell Immunol* (2009) **256**:79–85. doi:10.1016/j.cellimm.2009.01.007

93. Shedlock DJ, Talbott KT, Morrow MP, Ferraro B, Hokey DA, Muthumani K, Weiner DB. Ki-67 staining for determination of rhesus macaque T cell proliferative responses ex vivo. *Cytometry A* (2010) **77**:275–84. doi:10.1002/cyto.a.20857

94. Soares A, Govender L, Hughes J, Mavakla W, Kock M de, Barnard C, Pienaar B, Rensburg E van, Jacobs G, Khomba G, et al. Novel application of Ki67 to quantify antigen-specific in vitro lymphoproliferation. *J Immunol Methods* (2010) **362**:43–50. doi:10.1016/j.jim.2010.08.007

95. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. *J Cell Physiol* (2000) **182**:311–22. doi:10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9

96. Gerdes J, Lemke H, Baisch H, Wacker H, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. *J Immunol* (1984) **133**:1710–5.

97. Miller JD, Most RG van der, Akondy RS, Glidewell JT, Albott S, Masopust D, Murali-Krishna K, Mahar PL, Edupuganti S, Lalor S, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. *Immunity* (2008) **28**:710–22. doi:10.1016/j.immuni.2008.02.020

98. Stubbe M, Vanderheyde N, Goldman M, Marchant A. Antigen-Specific Central Memory CD4+ T Lymphocytes Produce Multiple Cytokines and Proliferate In Vivo in Humans. *J Immunol* (2006) **177**:8185–8190. doi:10.4049/jimmunol.177.11.8185

99. Cellerai C, Harari A, Vallelian F, Boyman O, Pantaleo G. Functional and phenotypic characterizationof tetanus toxoid-specific human CD4+ T cellsfollowing re-immunization. *Eur J Immunol* (2007) **37**:1129–1138. doi:10.1002/eji.200636885

100. Lyons A, Blake S, Doherty. Flow cytometric analysis of cell division by dilution of CFSE and related dyes. *Curr Protoc Cytom* (2013) **64**:9.11.1–9.11.12. doi:10.1002/0471142956.cy0911s64

101. Sallusto F, Geginat J, Lanzavecchia A. Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance. *Annu Rev Immunol* (2004) **22**:745–763. doi:10.1146/annurev.immunol.22.012703.104702

102. Anthony DD, Milkovich KA, Zhang W, Rodriguez B, Yonkers NL, Tary-Lehmann M, Lehmann PV. Dissecting the T Cell Response: Proliferation Assays vs. Cytokine Signatures by ELISPOT. *Cells* (2012) **1**:127–140. doi:10.3390/cells1020127

103. Lehmann PV, Zhang W. Unique strengths of ELISPOT for T cell diagnostics. *Methods Mol Biol* (2012) **792**:3–23. doi:10.1007/978-1-61779-325-7\_1

104. Ahlborg N, Axelsson B. Dual- and triple-color fluorospot. *Methods Mol Biol* (2012) **792**:77–85. doi:10.1007/978-1-61779-325-7\_6

105. Zhang W, Caspell R, Karulin A, Ahmad M, Haicheur N, Abdelsalam A, Johannesen K, Vignard V, Dudzik P, Georgakopoulou K, et al. ELISPOT assays provide reproducible results among different laboratories for T-cell immune monitoring—even in hands of ELISPOT-inexperienced investigators. *J Immunotoxicol* (2009) **6**:227–234. doi:10.3109/15476910903317546

106. Slota M, Lim J-B, Dang Y, Disis ML. ELISpot for measuring human immune responses to vaccines. *Expert Rev Vaccines* (2014) **10**:299–306. doi:10.1586/erv.10.169

107. Maecker HT, Hassler J, Payne JK, Summers A, Comatas K, Ghanayem M, Morse MA, Clay TM, Lyerly HK, Bhatia S, et al. Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. *BMC Immunol* (2008) **17**:9. doi:10.1186/1471-2172-9-9

108. Faucette AN, Unger BL, Gonik B, Chen K. Maternal vaccination: moving the science forward. *Human Reprod Update* (2015) **21**:119–135. doi:10.1093/humupd/dmu041